| Project/Area Number |
22K17259
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 57070:Developmental dentistry-related
|
|---|
| Research Institution | Health Sciences University of Hokkaido |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2022-04-01 – 2024-03-31
|
| Project Status |
Discontinued (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2024: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2023: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2022: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | malassez / amelogenin / minelarization / Amleogenin / Clone / Malassez |
|---|
| Outline of Research at the Start |
The importance of these three trials is that they establish a therapeutic strategy for the regeneration of the entire PDL (tissue around tooth) complex to restore the functions of the tooth. Combining these three phases could help develop a therapeutic strategy for the regeneration of hard tissue or PDL tissue, from basic research to clinical application.
|
| Outline of Annual Research Achievements |
In this study, we planned to isolate ERM from mice, but since it was difficult to isolate, we used amelogenin (Emdogain) extracted from pig tooth germ.
In my previous research, I reported that Amelogenin derived from porcine ERM plays a role in inhibiting the calcification of root and alveolar bone. However, it was also shown that amelogenin promotes the calcification of hydroxyapatite in enamel. This implies that the role of Amelogenin may differ based on where and when it is expressed in vivo.
|
